{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:29Z","timestamp":1740107429969,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00280-022-04417-3","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:03:06Z","timestamp":1648062186000},"page":"825-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"89","author":[{"given":"Weiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Cisternas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Garcia-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrett H.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Reschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"issue":"9","key":"4417_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1517\/14728222.12.9.1139","volume":"12","author":"LS Steelman","year":"2008","unstructured":"Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M et al (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12(9):1139\u20131165","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"4417_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627\u2013644","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4417_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","volume":"20","author":"KK Wong","year":"2010","unstructured":"Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20(1):87\u201390","journal-title":"Curr Opin Genet Dev"},{"issue":"41","key":"4417_CR4","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497\u20135510","journal-title":"Oncogene"},{"issue":"11","key":"4417_CR5","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","volume":"12","author":"N Liu","year":"2013","unstructured":"Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA et al (2013) BAY 80\u20136946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther 12(11):2319\u20132330","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4417_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-016-3198-0","volume":"79","author":"T Doi","year":"2017","unstructured":"Doi T, Fuse N, Yoshino T, Kojima T, Bando H, Miyamoto H et al (2017) A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol 79(1):89\u201398","journal-title":"Cancer Chemother Pharmacol"},{"issue":"35","key":"4417_CR7","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G et al (2017) Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 35(35):3898\u20133905","journal-title":"J Clin Oncol"},{"issue":"4","key":"4417_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows G, Lenz G et al (2020) Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 95(4):362\u2013371","journal-title":"Am J Hematol"},{"issue":"9","key":"4417_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE et al (2017) Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 28(9):2169\u20132178","journal-title":"Ann Oncol"},{"issue":"5","key":"4417_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, \u00d6zcan M, Lv F, Li W, Ya\u00f1ez E et al (2021) Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22(5):678\u2013689","journal-title":"Lancet Oncol"},{"issue":"3","key":"4417_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-017-3383-9","volume":"80","author":"M Gerisch","year":"2017","unstructured":"Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I et al (2017) Phamacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80\u20136946) in a mass balance study in healthy male volunteers. Cancer Chemother Pharmacol 80(3):535\u2013544","journal-title":"Cancer Chemother Pharmacol"},{"issue":"27","key":"4417_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"2","key":"4417_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/1535-7163.MCT-19-0466","volume":"19","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SAJ, Cunningham D et al (2020) On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Ther 19(2):468\u2013478","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"4417_CR14","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW et al (2016) First-in-human phase I study of copanlisib (BAY 80\u20136946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann Oncol 27(10):1928\u20131940","journal-title":"Ann Oncol"},{"issue":"3","key":"4417_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D et al (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282\u2013290","journal-title":"J Clin Oncol"},{"issue":"3","key":"4417_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s10637-013-0062-5","volume":"32","author":"CD Britten","year":"2014","unstructured":"Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K et al (2014) Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest New Drugs 32(3):510\u2013517","journal-title":"Invest New Drugs"},{"issue":"22","key":"4417_CR17","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC et al (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406\u20133413","journal-title":"Blood"},{"issue":"11","key":"4417_CR18","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008\u20131018","journal-title":"N Engl J Med"},{"issue":"8","key":"4417_CR19","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","volume":"21","author":"GI Shapiro","year":"2015","unstructured":"Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL et al (2015) First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res 21(8):1888\u20131895","journal-title":"Clin Cancer Res"},{"issue":"35","key":"4417_CR20","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K et al (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688\u20134695","journal-title":"J Clin Oncol"},{"issue":"23","key":"4417_CR21","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","volume":"30","author":"NL Busaidy","year":"2012","unstructured":"Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA et al (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30(23):2919\u20132928","journal-title":"J Clin Oncol"},{"issue":"Pt 3","key":"4417_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1042\/bj3330471","volume":"333","author":"PR Shepherd","year":"1998","unstructured":"Shepherd PR, Withers DJ, Siddle K (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333(Pt 3):471\u2013490","journal-title":"Biochem J"},{"issue":"1","key":"4417_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","volume":"15","author":"MC Crouthamel","year":"2009","unstructured":"Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ et al (2009) Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 15(1):217\u2013225","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4417_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125","author":"ZA Knight","year":"2006","unstructured":"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733\u2013747","journal-title":"Cell"},{"issue":"3","key":"4417_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1681\/ASN.2006050541","volume":"18","author":"T Quaschning","year":"2007","unstructured":"Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T et al (2007) Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic\/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 18(3):730\u2013740","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4417_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCRESAHA.108.189316","volume":"104","author":"JD Symons","year":"2009","unstructured":"Symons JD, McMillin SL, Riehle C, Tanner J, Palionyte M, Hillas E et al (2009) Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res 104(9):1085\u20131094","journal-title":"Circ Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04417-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04417-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04417-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:03:28Z","timestamp":1653555808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04417-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4417"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04417-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yi Niu, Galia Cisternas, Funan Huang, Jose Garcia-Vargas, Barrett H Childs, Aruna Mehra, and Susanne Reschke are employees of Bayer. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}